Current Status of Estrogen Therapy for Prostatic Carcinoma
- 1 March 1972
- journal article
- clinical trial
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 51 (3), 140-145
- https://doi.org/10.1080/00325481.1972.11698173
Abstract
Studies reevaluating the effects of estrogen in treating prostatic carcinoma have shown that while estrogen usually increases the duration and quality of survival, it appears to be associated with an increase in fatal and nonfatal thromboembolic complications. Findings also show that 1.0 mg of diethylstilbestrol daily is probably as effective against metastatic cancer of the prostate as 5.0 mg, and is associated with a lower incidence of cardiovascular complications.Keywords
This publication has 8 references indexed in Scilit:
- The Coronary Drug ProjectPublished by American Medical Association (AMA) ,1970
- Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostateCancer, 1970
- Estrogen treatment for cancer of the prostate.Early results with 3 doses of diethylstilbestrol and placeboCancer, 1970
- Effects of Oral ContraceptivesAnnual Review of Pharmacology, 1969
- Carcinoma of the Prostate: Treatment ComparisonsJournal of Urology, 1967
- Estrogen Dosage Effects on Serum Proteins: A Longitudinal StudyJournal of Clinical Endocrinology & Metabolism, 1967
- Risk of thromboembolic disease in women taking oral contraceptives. A preliminary communication to the Medical Research Council by a Subcommittee.BMJ, 1967
- Elevation of Certain Plasma Proteins in Man Following Estrogen Administration: A Dose-Response RelationshipJournal of Clinical Endocrinology & Metabolism, 1965